- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Drugs for HIV will have significant change from previous year. By the most conservative estimates of global Drugs for HIV market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Drugs for HIV market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for HIV market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Drugs for HIV, covering the supply chain analysis, impact assessment to the Drugs for HIV market size growth rate in several scenarios, and the measures to be undertaken by Drugs for HIV companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Integrase Inhibitors
Combination HIV Medicines
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
ViiV Healthcare
Gilead Sciences, Inc
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp
Genentech, Inc.
Theratechnologies Inc.
AbbVie Inc.
Mylan Pharmaceuticals Inc.
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Drugs for HIV consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Drugs for HIV market by identifying its various subsegments.
Focuses on the key global Drugs for HIV manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for HIV with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for HIV submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Drugs for HIV?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for HIV Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for HIV Consumption 2015-2025
2.1.2 Drugs for HIV Consumption CAGR by Region
2.2 Drugs for HIV Segment by Type
2.2.1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2.2 Integrase Inhibitors
2.2.3 Combination HIV Medicines
2.2.4 Others
2.3 Drugs for HIV Consumption by Type
2.3.1 Global Drugs for HIV Consumption Market Share by Type (2015-2020)
2.3.2 Global Drugs for HIV Revenue and Market Share by Type (2015-2020)
2.3.3 Global Drugs for HIV Sale Price by Type (2015-2020)
2.4 Drugs for HIV Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.4.4 Others
2.5 Drugs for HIV Consumption by Application
2.5.1 Global Drugs for HIV Consumption Market Share by Type (2015-2020)
2.5.2 Global Drugs for HIV Value and Market Share by Type (2015-2020)
2.5.3 Global Drugs for HIV Sale Price by Type (2015-2020)
3 Global Drugs for HIV by Company
3.1 Global Drugs for HIV Sales Market Share by Company
3.1.1 Global Drugs for HIV Sales by Company (2018-2020)
3.1.2 Global Drugs for HIV Sales Market Share by Company (2018-2020)
3.2 Global Drugs for HIV Revenue Market Share by Company
3.2.1 Global Drugs for HIV Revenue by Company (2018-2020)
3.2.2 Global Drugs for HIV Revenue Market Share by Company (2018-2020)
3.3 Global Drugs for HIV Sale Price by Company
3.4 Global Drugs for HIV Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Drugs for HIV Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Drugs for HIV Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Drugs for HIV by Regions
4.1 Drugs for HIV by Regions
4.2 Americas Drugs for HIV Consumption Growth
4.3 APAC Drugs for HIV Consumption Growth
4.4 Europe Drugs for HIV Consumption Growth
4.5 Middle East & Africa Drugs for HIV Consumption Growth
5 Americas
5.1 Americas Drugs for HIV Consumption by Countries
5.1.1 Americas Drugs for HIV Consumption by Countries (2015-2020)
5.1.2 Americas Drugs for HIV Value by Countries (2015-2020)
5.2 Americas Drugs for HIV Consumption by Type
5.3 Americas Drugs for HIV Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Drugs for HIV Consumption by Regions
6.1.1 APAC Drugs for HIV Consumption by Regions (2015-2020)
6.1.2 APAC Drugs for HIV Value by Regions (2015-2020)
6.2 APAC Drugs for HIV Consumption by Type
6.3 APAC Drugs for HIV Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Drugs for HIV by Countries
7.1.1 Europe Drugs for HIV Consumption by Countries (2015-2020)
7.1.2 Europe Drugs for HIV Value by Countries (2015-2020)
7.2 Europe Drugs for HIV Consumption by Type
7.3 Europe Drugs for HIV Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Drugs for HIV by Countries
8.1.1 Middle East & Africa Drugs for HIV Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Drugs for HIV Value by Countries (2015-2020)
8.2 Middle East & Africa Drugs for HIV Consumption by Type
8.3 Middle East & Africa Drugs for HIV Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Drugs for HIV Distributors
10.3 Drugs for HIV Customer
11 Global Drugs for HIV Market Forecast
11.1 Global Drugs for HIV Consumption Forecast (2021-2025)
11.2 Global Drugs for HIV Forecast by Regions
11.2.1 Global Drugs for HIV Forecast by Regions (2021-2025)
11.2.2 Global Drugs for HIV Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Drugs for HIV Forecast by Type
11.8 Global Drugs for HIV Forecast by Application
12 Key Players Analysis
12.1 ViiV Healthcare
12.1.1 Company Information
12.1.2 Drugs for HIV Product Offered
12.1.3 ViiV Healthcare Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 ViiV Healthcare Latest Developments
12.2 Gilead Sciences, Inc
12.2.1 Company Information
12.2.2 Drugs for HIV Product Offered
12.2.3 Gilead Sciences, Inc Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Gilead Sciences, Inc Latest Developments
12.3 Bristol-Myers Squibb Company
12.3.1 Company Information
12.3.2 Drugs for HIV Product Offered
12.3.3 Bristol-Myers Squibb Company Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Bristol-Myers Squibb Company Latest Developments
12.4 Janssen Pharmaceuticals, Inc.
12.4.1 Company Information
12.4.2 Drugs for HIV Product Offered
12.4.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Janssen Pharmaceuticals, Inc. Latest Developments
12.5 Merck Sharp & Dohme Corp
12.5.1 Company Information
12.5.2 Drugs for HIV Product Offered
12.5.3 Merck Sharp & Dohme Corp Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Merck Sharp & Dohme Corp Latest Developments
12.6 Genentech, Inc.
12.6.1 Company Information
12.6.2 Drugs for HIV Product Offered
12.6.3 Genentech, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Genentech, Inc. Latest Developments
12.7 Theratechnologies Inc.
12.7.1 Company Information
12.7.2 Drugs for HIV Product Offered
12.7.3 Theratechnologies Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Theratechnologies Inc. Latest Developments
12.8 AbbVie Inc.
12.8.1 Company Information
12.8.2 Drugs for HIV Product Offered
12.8.3 AbbVie Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 AbbVie Inc. Latest Developments
12.9 Mylan Pharmaceuticals Inc.
12.9.1 Company Information
12.9.2 Drugs for HIV Product Offered
12.9.3 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Mylan Pharmaceuticals Inc. Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for HIV Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Drugs for HIV Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Drugs for HIV Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 7. Major Players of Integrase Inhibitors
Table 8. Major Players of Combination HIV Medicines
Table 9. Major Players of Others
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Drugs for HIV Consumption Market Share by Type (2015-2020)
Table 12. Global Drugs for HIV Revenue by Type (2015-2020) ($ million)
Table 13. Global Drugs for HIV Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Drugs for HIV Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Drugs for HIV Consumption Market Share by Application (2015-2020)
Table 17. Global Drugs for HIV Value by Application (2015-2020)
Table 18. Global Drugs for HIV Value Market Share by Application (2015-2020)
Table 19. Global Drugs for HIV Sale Price by Application (2015-2020)
Table 20. Global Drugs for HIV Sales by Company (2017-2019) (K Units)
Table 21. Global Drugs for HIV Sales Market Share by Company (2017-2019)
Table 22. Global Drugs for HIV Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Drugs for HIV Revenue Market Share by Company (2017-2019)
Table 24. Global Drugs for HIV Sale Price by Company (2017-2019)
Table 25. Global Drugs for HIV Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Drugs for HIV Products Offered
Table 27. Drugs for HIV Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Drugs for HIV Consumption by Regions 2015-2020 (K Units)
Table 29. Global Drugs for HIV Consumption Market Share by Regions 2015-2020
Table 30. Global Drugs for HIV Value by Regions 2015-2020 ($ Millions)
Table 31. Global Drugs for HIV Value Market Share by Regions 2015-2020
Table 32. Americas Drugs for HIV Consumption by Countries (2015-2020) (K Units)
Table 33. Americas Drugs for HIV Consumption Market Share by Countries (2015-2020)
Table 34. Americas Drugs for HIV Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Drugs for HIV Value Market Share by Countries (2015-2020)
Table 36. Americas Drugs for HIV Consumption by Type (2015-2020) (K Units)
Table 37. Americas Drugs for HIV Consumption Market Share by Type (2015-2020)
Table 38. Americas Drugs for HIV Consumption by Application (2015-2020) (K Units)
Table 39. Americas Drugs for HIV Consumption Market Share by Application (2015-2020)
Table 40. APAC Drugs for HIV Consumption by Countries (2015-2020) (K Units)
Table 41. APAC Drugs for HIV Consumption Market Share by Countries (2015-2020)
Table 42. APAC Drugs for HIV Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Drugs for HIV Value Market Share by Regions (2015-2020)
Table 44. APAC Drugs for HIV Consumption by Type (2015-2020) (K Units)
Table 45. APAC Drugs for HIV Consumption Market Share by Type (2015-2020)
Table 46. APAC Drugs for HIV Consumption by Application (2015-2020) (K Units)
Table 47. APAC Drugs for HIV Consumption Market Share by Application (2015-2020)
Table 48. Europe Drugs for HIV Consumption by Countries (2015-2020) (K Units)
Table 49. Europe Drugs for HIV Consumption Market Share by Countries (2015-2020)
Table 50. Europe Drugs for HIV Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Drugs for HIV Value Market Share by Countries (2015-2020)
Table 52. Europe Drugs for HIV Consumption by Type (2015-2020) (K Units)
Table 53. Europe Drugs for HIV Consumption Market Share by Type (2015-2020)
Table 54. Europe Drugs for HIV Consumption by Application (2015-2020) (K Units)
Table 55. Europe Drugs for HIV Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Drugs for HIV Consumption by Countries (2015-2020) (K Units)
Table 57. Middle East & Africa Drugs for HIV Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Drugs for HIV Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Drugs for HIV Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Drugs for HIV Consumption by Type (2015-2020) (K Units)
Table 61. Middle East & Africa Drugs for HIV Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Drugs for HIV Consumption by Application (2015-2020) (K Units)
Table 63. Middle East & Africa Drugs for HIV Consumption Market Share by Application (2015-2020)
Table 64. Drugs for HIV Distributors List
Table 65. Drugs for HIV Customer List
Table 66. Global Drugs for HIV Consumption Forecast by Countries (2021-2025) (K Units)
Table 67. Global Drugs for HIV Consumption Market Forecast by Regions
Table 68. Global Drugs for HIV Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Drugs for HIV Value Market Share Forecast by Regions
Table 70. Global Drugs for HIV Consumption Forecast by Type (2021-2025) (K Units)
Table 71. Global Drugs for HIV Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Drugs for HIV Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Drugs for HIV Value Market Share Forecast by Type (2021-2025)
Table 74. Global Drugs for HIV Consumption Forecast by Application (2021-2025) (K Units)
Table 75. Global Drugs for HIV Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Drugs for HIV Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Drugs for HIV Value Market Share Forecast by Application (2021-2025)
Table 78. ViiV Healthcare Product Offered
Table 79. ViiV Healthcare Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 80. ViiV Healthcare Main Business
Table 81. ViiV Healthcare Latest Developments
Table 82. ViiV Healthcare Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 83. Gilead Sciences, Inc Product Offered
Table 84. Gilead Sciences, Inc Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 85. Gilead Sciences, Inc Main Business
Table 86. Gilead Sciences, Inc Latest Developments
Table 87. Gilead Sciences, Inc Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 88. Bristol-Myers Squibb Company Product Offered
Table 89. Bristol-Myers Squibb Company Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 90. Bristol-Myers Squibb Company Main Business
Table 91. Bristol-Myers Squibb Company Latest Developments
Table 92. Bristol-Myers Squibb Company Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 93. Janssen Pharmaceuticals, Inc. Product Offered
Table 94. Janssen Pharmaceuticals, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 95. Janssen Pharmaceuticals, Inc. Main Business
Table 96. Janssen Pharmaceuticals, Inc. Latest Developments
Table 97. Janssen Pharmaceuticals, Inc. Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 98. Merck Sharp & Dohme Corp Product Offered
Table 99. Merck Sharp & Dohme Corp Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 100. Merck Sharp & Dohme Corp Main Business
Table 101. Merck Sharp & Dohme Corp Latest Developments
Table 102. Merck Sharp & Dohme Corp Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 103. Genentech, Inc. Product Offered
Table 104. Genentech, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 105. Genentech, Inc. Main Business
Table 106. Genentech, Inc. Latest Developments
Table 107. Genentech, Inc. Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 108. Theratechnologies Inc. Product Offered
Table 109. Theratechnologies Inc. Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 110. Theratechnologies Inc. Main Business
Table 111. Theratechnologies Inc. Latest Developments
Table 112. Theratechnologies Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 113. AbbVie Inc. Product Offered
Table 114. AbbVie Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 115. AbbVie Inc. Main Business
Table 116. AbbVie Inc. Latest Developments
Table 117. AbbVie Inc. Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 118. Mylan Pharmaceuticals Inc. Product Offered
Table 119. Mylan Pharmaceuticals Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 120. Mylan Pharmaceuticals Inc. Main Business
Table 121. Mylan Pharmaceuticals Inc. Latest Developments
Table 122. Mylan Pharmaceuticals Inc. Basic Information, Company Total Revenue (in $ million), Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Drugs for HIV
Figure 2. Drugs for HIV Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Drugs for HIV Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Drugs for HIV Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Figure 7. Product Picture of Integrase Inhibitors
Figure 8. Product Picture of Combination HIV Medicines
Figure 9. Product Picture of Others
Figure 10. Global Drugs for HIV Consumption Market Share by Type (2015-2020)
Figure 11. Global Drugs for HIV Value Market Share by Type (2015-2020)
Figure 12. Drugs for HIV Consumed in Hospital Pharmacies
Figure 13. Global Drugs for HIV Market: Hospital Pharmacies (2015-2020) (K Units)
Figure 14. Global Drugs for HIV Market: Hospital Pharmacies (2015-2020) ($ Millions)
Figure 15. Drugs for HIV Consumed in Retail Pharmacies
Figure 16. Global Drugs for HIV Market: Retail Pharmacies (2015-2020) (K Units)
Figure 17. Global Drugs for HIV Market: Retail Pharmacies (2015-2020) ($ Millions)
Figure 18. Drugs for HIV Consumed in Online Pharmacies
Figure 19. Global Drugs for HIV Market: Online Pharmacies (2015-2020) (K Units)
Figure 20. Global Drugs for HIV Market: Online Pharmacies (2015-2020) ($ Millions)
Figure 21. Drugs for HIV Consumed in Others
Figure 22. Global Drugs for HIV Market: Others (2015-2020) (K Units)
Figure 23. Global Drugs for HIV Market: Others (2015-2020) ($ Millions)
Figure 24. Global Drugs for HIV Consumption Market Share by Application (2015-2020)
Figure 25. Global Drugs for HIV Value Market Share by Application (2015-2020)
Figure 26. Global Drugs for HIV Sales Market Share by Company in 2017
Figure 27. Global Drugs for HIV Sales Market Share by Company in 2019
Figure 28. Global Drugs for HIV Revenue Market Share by Company in 2017
Figure 29. Global Drugs for HIV Revenue Market Share by Company in 2019
Figure 30. Global Drugs for HIV Sale Price by Company in 2019
Figure 31. Global Drugs for HIV Consumption Market Share by Regions 2015-2020
Figure 32. Global Drugs for HIV Value Market Share by Regions 2015-2020
Figure 33. Americas Drugs for HIV Consumption 2015-2020 (K Units)
Figure 34. Americas Drugs for HIV Value 2015-2020 ($ Millions)
Figure 35. APAC Drugs for HIV Consumption 2015-2020 (K Units)
Figure 36. APAC Drugs for HIV Value 2015-2020 ($ Millions)
Figure 37. Europe Drugs for HIV Consumption 2015-2020 (K Units)
Figure 38. Europe Drugs for HIV Value 2015-2020 ($ Millions)
Figure 39. Middle East & Africa Drugs for HIV Consumption 2015-2020 (K Units)
Figure 40. Middle East & Africa Drugs for HIV Value 2015-2020 ($ Millions)
Figure 41. Americas Drugs for HIV Consumption Market Share by Countries in 2019
Figure 42. Americas Drugs for HIV Value Market Share by Countries in 2019
Figure 43. Americas Drugs for HIV Consumption Market Share by Type in 2019
Figure 44. Americas Drugs for HIV Consumption Market Share by Application in 2019
Figure 45. United States Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 46. United States Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 47. Canada Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 48. Canada Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 49. Mexico Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 50. Mexico Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 51. APAC Drugs for HIV Consumption Market Share by Countries in 2019
Figure 52. APAC Drugs for HIV Value Market Share by Regions in 2019
Figure 53. APAC Drugs for HIV Consumption Market Share by Type in 2019
Figure 54. APAC Drugs for HIV Consumption Market Share by Application in 2019
Figure 55. China Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 56. China Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 57. Japan Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 58. Japan Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 59. Korea Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 60. Korea Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 61. Southeast Asia Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 62. Southeast Asia Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 63. India Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 64. India Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 65. Australia Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 66. Australia Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 67. Europe Drugs for HIV Consumption Market Share by Countries in 2019
Figure 68. Europe Drugs for HIV Value Market Share by Countries in 2019
Figure 69. Europe Drugs for HIV Consumption Market Share by Type in 2019
Figure 70. Europe Drugs for HIV Consumption Market Share by Application in 2019
Figure 71. Germany Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 72. Germany Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 73. France Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 74. France Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 75. UK Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 76. UK Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 77. Italy Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 78. Italy Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 79. Russia Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 80. Russia Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 81. Middle East & Africa Drugs for HIV Consumption Market Share by Countries in 2019
Figure 82. Middle East & Africa Drugs for HIV Value Market Share by Countries in 2019
Figure 83. Middle East & Africa Drugs for HIV Consumption Market Share by Type in 2019
Figure 84. Middle East & Africa Drugs for HIV Consumption Market Share by Application in 2019
Figure 85. Egypt Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 86. Egypt Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 87. South Africa Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 88. South Africa Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 89. Israel Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 90. Israel Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 91. Turkey Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 92. Turkey Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 93. GCC Countries Drugs for HIV Consumption Growth 2015-2020 (K Units)
Figure 94. GCC Countries Drugs for HIV Value Growth 2015-2020 ($ Millions)
Figure 95. Global Drugs for HIV Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 96. Global Drugs for HIV Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 97. Americas Drugs for HIV Consumption 2021-2025 (K Units)
Figure 98. Americas Drugs for HIV Value 2021-2025 ($ Millions)
Figure 99. APAC Drugs for HIV Consumption 2021-2025 (K Units)
Figure 100. APAC Drugs for HIV Value 2021-2025 ($ Millions)
Figure 101. Europe Drugs for HIV Consumption 2021-2025 (K Units)
Figure 102. Europe Drugs for HIV Value 2021-2025 ($ Millions)
Figure 103. Middle East & Africa Drugs for HIV Consumption 2021-2025 (K Units)
Figure 104. Middle East & Africa Drugs for HIV Value 2021-2025 ($ Millions)
Figure 105. United States Drugs for HIV Consumption 2021-2025 (K Units)
Figure 106. United States Drugs for HIV Value 2021-2025 ($ Millions)
Figure 107. Canada Drugs for HIV Consumption 2021-2025 (K Units)
Figure 108. Canada Drugs for HIV Value 2021-2025 ($ Millions)
Figure 109. Mexico Drugs for HIV Consumption 2021-2025 (K Units)
Figure 110. Mexico Drugs for HIV Value 2021-2025 ($ Millions)
Figure 111. Brazil Drugs for HIV Consumption 2021-2025 (K Units)
Figure 112. Brazil Drugs for HIV Value 2021-2025 ($ Millions)
Figure 113. China Drugs for HIV Consumption 2021-2025 (K Units)
Figure 114. China Drugs for HIV Value 2021-2025 ($ Millions)
Figure 115. Japan Drugs for HIV Consumption 2021-2025 (K Units)
Figure 116. Japan Drugs for HIV Value 2021-2025 ($ Millions)
Figure 117. Korea Drugs for HIV Consumption 2021-2025 (K Units)
Figure 118. Korea Drugs for HIV Value 2021-2025 ($ Millions)
Figure 119. Southeast Asia Drugs for HIV Consumption 2021-2025 (K Units)
Figure 120. Southeast Asia Drugs for HIV Value 2021-2025 ($ Millions)
Figure 121. India Drugs for HIV Consumption 2021-2025 (K Units)
Figure 122. India Drugs for HIV Value 2021-2025 ($ Millions)
Figure 123. Australia Drugs for HIV Consumption 2021-2025 (K Units)
Figure 124. Australia Drugs for HIV Value 2021-2025 ($ Millions)
Figure 125. Germany Drugs for HIV Consumption 2021-2025 (K Units)
Figure 126. Germany Drugs for HIV Value 2021-2025 ($ Millions)
Figure 127. France Drugs for HIV Consumption 2021-2025 (K Units)
Figure 128. France Drugs for HIV Value 2021-2025 ($ Millions)
Figure 129. UK Drugs for HIV Consumption 2021-2025 (K Units)
Figure 130. UK Drugs for HIV Value 2021-2025 ($ Millions)
Figure 131. Italy Drugs for HIV Consumption 2021-2025 (K Units)
Figure 132. Italy Drugs for HIV Value 2021-2025 ($ Millions)
Figure 133. Russia Drugs for HIV Consumption 2021-2025 (K Units)
Figure 134. Russia Drugs for HIV Value 2021-2025 ($ Millions)
Figure 135. Spain Drugs for HIV Consumption 2021-2025 (K Units)
Figure 136. Spain Drugs for HIV Value 2021-2025 ($ Millions)
Figure 137. Egypt Drugs for HIV Consumption 2021-2025 (K Units)
Figure 138. Egypt Drugs for HIV Value 2021-2025 ($ Millions)
Figure 139. South Africa Drugs for HIV Consumption 2021-2025 (K Units)
Figure 140. South Africa Drugs for HIV Value 2021-2025 ($ Millions)
Figure 141. Israel Drugs for HIV Consumption 2021-2025 (K Units)
Figure 142. Israel Drugs for HIV Value 2021-2025 ($ Millions)
Figure 143. Turkey Drugs for HIV Consumption 2021-2025 (K Units)
Figure 144. Turkey Drugs for HIV Value 2021-2025 ($ Millions)
Figure 145. GCC Countries Drugs for HIV Consumption 2021-2025 (K Units)
Figure 146. GCC Countries Drugs for HIV Value 2021-2025 ($ Millions)
Figure 147. ViiV Healthcare Drugs for HIV Market Share (2018-2020)
Figure 148. Gilead Sciences, Inc Drugs for HIV Market Share (2018-2020)
Figure 149. Bristol-Myers Squibb Company Drugs for HIV Market Share (2018-2020)
Figure 150. Janssen Pharmaceuticals, Inc. Drugs for HIV Market Share (2018-2020)
Figure 151. Merck Sharp & Dohme Corp Drugs for HIV Market Share (2018-2020)
Figure 152. Genentech, Inc. Drugs for HIV Market Share (2018-2020)
Figure 153. Theratechnologies Inc. Drugs for HIV Market Share (2018-2020)
Figure 154. AbbVie Inc. Drugs for HIV Market Share (2018-2020)
Figure 155. Mylan Pharmaceuticals Inc. Drugs for HIV Market Share (2018-2020)
Please feel free to write an email to us or to use our electronic ticketing system.
